Physician profile
John Sun
NPI 1821082165
$4,200.13
in general payments reported to CMS, 2019-2025
20 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $561 · 2021: $904 · 2022: $229 · 2023: $277 · 2024: $771 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.90 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,362.87 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $1,016.03 | 2019-2024 | Otezla, Repatha, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $422.58 | 2021-2024 | |
| Novo Nordisk INC | $233.18 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $232.66 | 2019-2021 | |
| Astellas Pharma US INC | $182.48 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $134.94 | 2019-2020 | |
| Abbvie INC. | $115.24 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.63 | 2020-2022 | |
| Pfizer INC. | $80.99 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $74.06 | 2020-2021 | |
| Allergan, INC. | $68.24 | 2019-2020 | |
| Gilead Sciences, INC. | $32.80 | 2021 | |
| Glaxosmithkline, LLC. | $31.03 | 2023 | Pediarix, Bexsero, Menveo |
| Novartis Pharmaceuticals Corporation | $24.71 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $20.77 | 2020 | |
| Ironshore Pharmaceuticals INC. | $19.15 | 2019 | |
| Merck Sharp & Dohme LLC | $16.44 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.